LianBio Sponsored ADR (LIANY) AI Stock Analysis

LianBio Sponsored ADR

(Other OTC:LIANY)

Select Model

Rating:45Neutral

Action:N/A

Date:01/25/25

LianBio's overall stock score is driven by its financial resilience due to strong cash reserves and equity position, but severely offset by its lack of revenue generation and persistent operational losses. The technical analysis indicates a bearish market sentiment, and the extremely low P/E ratio reflects market doubts about future profitability. The absence of significant earnings call data or corporate events means these factors do not influence the current score.

Positive Factors

Strong Cash ReservesStrong cash reserves provide financial resilience, allowing LianBio to invest in strategic initiatives and weather operational challenges.

Negative Factors

Lack of Revenue GenerationPersistent lack of revenue generation raises concerns about LianBio's ability to sustain operations without strategic changes.

LianBio Sponsored ADR (LIANY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.80M
Dividend Yield: ―
Average Volume (3M): 17.27K
Price to Earnings (P/E): 1.0
Beta (1Y): 0.18
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 163
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

LianBio Sponsored ADR Business Overview & Revenue Model

Company Description

LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations a...

How the Company Makes Money

LianBio generates revenue primarily through strategic partnerships and collaboration agreements with global pharmaceutical and biotechnology companies. The company acquires the rights to develop and commercialize promising drug candidates in specific...

LianBio Sponsored ADR Technical Analysis

Technical Analysis SentimentNegative

Last Price0.04

Price Trends

50DMA0.05Negative

100DMA0.07Negative

200DMA0.09Negative

Market Momentum

MACD-0.00Positive

RSI39.28Neutral

STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIANY, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 39.28 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LIANY.

LianBio Sponsored ADR Risk Analysis

LianBio Sponsored ADR disclosed 114 risk factors in its most recent earnings report. LianBio Sponsored ADR reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.CybersecurityQ2, 2023

2.Cybersecurity reviewQ2, 2023

3.Cross-border data transfer requirements (security assessment; certification; standard contract)Q2, 2023

LianBio Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

LIANY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LIANY	45Neutral	$4.85M	0.98	11.78%	―	―	―

* Healthcare Sector Average

Performance Comparison

LIANY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
LIANY	Lianbio Sponsored Adr	0.04	-0.03	-41.33%
VIVS	Vivosim Labs Inc	0.15	-2.21	-93.47%
PMCB	Pharmacyte Biotech, Inc.	0.30	-0.61	-67.07%
SPRC	SciSparc Ltd.	0.68	-29.20	-97.74%
PLRZ	Polyrizon Ltd.	10.75	4.81	80.98%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 25, 2025

LianBio Sponsored ADR AI Stock Analysis